CardioSource WorldNews October 2015 | Page 33

Take your PAH and CTEPH patients farther with Adempas In pulmonary arterial hypertension (PAH), (WHO Group 1) 36m improvement (mean) in 6-minute walk distance (6MWD) over placebo at Week 12 (95% Confidence Interval (CI): 20m-52m; p<0.0001) In inoperable and persistent/recurrent chronic thromboembolic hypertension (CTEPH), (WHO Group 4) 46m improvement (mean) in 6MWD over placebo at Week 16 (95% CI: 25m-67m; p<0.0001) Randomized, multicenter, placebo-controlled clinical study of 443 adult PAH patients with predominantly WHO Functional Class II-III. The primary endpoint was change from baseline in 6MWD at 12 weeks. Randomized, multicenter, placebo-controlled clinical study of 261 adult patients with persistent/recurrent CTEPH after surgery or who were inoperable. The primary endpoint was change from baseline in 6MWD at 16 weeks. CONTRAINDICATIONS (continued) Bleeding. In the placebo-controlled clinical trials, serious bleeding occurred in 2.4% of patients taking Adempas compared to 0% of placebo patients. Serious hemoptysis occurred in 5 (1%) patients